Clinical Trials Browser

Phase 2/3 × Docetaxel × Head & Neck × Clear all

NCT05063552 2026-03-18

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02923258 2024-06-20

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

Phase 2/3 Completed

224 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00261703 2012-05-11

Docetaxel in Head and Neck Cancer

Phase 2/3 Completed

439 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

568 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local